ITGAX and myasthenia gravis: The majority of CD11c+ B cells were comprised of switched memory B cells (23), with DN B cells making up only a small fraction (between 12.47% in controls, 17.70% in rituximab-naïve MuSK-MG, 10.21% in rituximab treated MuSK-MG, and highest in 22.38% in AChR-MG) (Figures 2C–E).